Featured Research

from universities, journals, and other organizations

No ESKAPE! New Drugs Against MRSA, Other Superbugs Still Lacking

Date:
December 9, 2008
Source:
Infectious Diseases Society of America
Summary:
Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics.

This scanning electron micrograph (SEM) depicted numerous clumps of methicillin-resistant Staphylococcus aureus bacteria, commonly referred to by the acronym, MRSA; Magnified 2381x.
Credit: CDC / Janice Haney Carr

Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics.

Related Articles


The ESKAPE pathogens—as these six bad bugs have been dubbed—are still on the loose more than four years after the Infectious Diseases Society of America (IDSA) first drew attention to the growing shortage of effective antibiotics. As the crisis of antibiotic resistance continues to grow, the latest IDSA "Bad Bugs, No Drugs" report examines the trickle of new antibiotics in the research and development (R&D) pipeline and proposes steps to tackle the shortage.

"The six bad bugs we call the ESKAPE bacteria—Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—are among the biggest threats infectious diseases physicians face today," said Helen Boucher, MD, of Tufts Medical Center in Boston, lead author of the new report, published in the January 1 issue of Clinical Infectious Diseases and now available online. "We desperately need new drugs to fight them. But we also need cooperation among industry, academia, and government to create a sustainable R&D infrastructure that will fill the pipeline to meet today's needs and keep it filled with drugs that tackle tomorrow's infectious diseases threats."

Amid the continuing downward trend in new antibiotics, the new report shows a few signs of hope. The Food and Drug Administration (FDA) has approved a small number of new antibiotics in the last several years, most of them active against methicillin-resistant Staphylococcus aureus (MRSA). However, just one can be taken orally (the rest are intravenous); they are too toxic for some patients to handle; and resistance to them is already beginning to emerge.

But the medicine cabinet is particularly bare when it comes to Acinetobacter, Klebsiella, and Pseudomonas. Called "gram negative" for the way they react to a common staining test used to identify bacteria in a microscope, they attack some of the most vulnerable patients, including those in intensive care units and long-term care facilities, burn victims, and those with cystic fibrosis. These especially bad bugs are becoming more and more resistant to antibiotics. Physicians are now facing some strains that are resistant to every antibiotic in the arsenal. Only one new drug was approved for gram-negative infections last year, and resistance already exists to other drugs in its class.

In its 2004 report, "Bad Bugs, No Drugs: As Antibiotic Development Stagnates…A Public Health Crisis Brews," IDSA detailed the complex mix of factors driving drug makers out of the antibiotics market. One factor is the high cost of drug development coupled with the low rate of return on investment antibiotics provide compared with drugs for chronic conditions such as heart disease, diabetes, or cancer. Furthermore, regulations for new drug approvals have been murky, and drug manufacturers have been reluctant to gamble.

In the new report, IDSA outlines steps Congress should take to make antibiotics a more attractive business proposition. The report applauds FDA for taking steps toward clarifying regulations for drug approvals, and urges more movement in this direction. IDSA also urges Congress to pass the Strategies To Address Antimicrobial Resistance (STAAR) Act, a bill designed to improve research, surveillance, and prevention of antimicrobial-resistant germs.

"More than four years after our first report, the bad bugs are getting worse, and we still don't have the drugs we need," Dr. Boucher said. "We need new tools to fight the ESKAPE bugs now. But there will always be bad bugs. We need industry, academia, and government working together so we are never again left with no drugs for bad bugs."

The ESKAPE Bacteria

According to the latest data from the Centers for Disease Control and Prevention (CDC), the six ESKAPE bacteria are responsible for two thirds of all health care-associated infections (HAIs). They are:

Enterococcus species: Enterococci were responsible for one out of eight HAIs in 2006-2007. A 2004 study found about two thirds of E. faecium bloodstream infections were resistant to vancomycin, one of the most commonly used antibiotics to treat enterococcal infections. Some physicians are treating vancomycin-resistant E. faecium with the new antibiotics linezolid, daptomycin, and tigecycline, but these drugs have not been studied extensively for use against these infections. Furthermore, many patients cannot tolerate them.

Staphylococcus aureus: The only household name among the ESKAPE bugs, methicillin-resistant Staphylococcus aureus (MRSA) outbreaks have been reported among otherwise-healthy athletes, military recruits, school children, and others. MRSA caused an estimated 94,000 invasive infections—more than 19,000 of them fatal—in 2005, according to a recent study by CDC. MRSA is a serious and growing threat in hospitals and other health care facilities, but this study found 14 percent of patients had no obvious exposure to a health care facility.

MRSA has drawn more attention from the pharmaceutical industry than any of the other ESKAPE bugs. Several new drugs are effective against these infections. However, all but one are given intravenously and are primarily to be used in hospitals. Many patients cannot tolerate these potent drugs. Also, only one drug in the pipeline works using a mechanism different from the ones to which some bad bugs have already developed resistance.

Klebsiella species: These gram-negative bacteria cause infections in the urinary, biliary, and gastrointestinal tracts, and in trauma wounds. Klebsiella species and their gram-negative cousin E. coli together accounted for 18 percent of all HAIs in 2006-2007, and a growing proportion of these two bad bugs carry resistance to a remarkable spectrum of antibiotics. Of the very few drugs in late-stage development, none works by a novel mechanism.

Acinetobacter baumannii: Drug resistance is a major problem in Acinetobacter infections, which are responsible for about 3 percent of all HAIs,. Soldiers are returning from Iraq and Afghanistan with cases of highly resistant Acinetobacter wound infections. Strains have emerged that are resistant to all but the most toxic drugs. Physicians have been forced to resort to an old drug that is known to cause organ damage, and resistance is even developing to this drug. Yet there is nothing in development against Acinetobacter.

Pseudomonas aeruginosa: Pseudomonas is a particular problem for patients on respirators and those with cystic fibrosis. Eight percent of all HAIs are caused by P. aeruginosa, and one quarter of these are resistant to carbapenems, a class of antibiotics commonly used for these infections. There are no new drugs in development for these highly resistant infections.

Enterobacter species: One in 20 HAIs is caused by this group of bacteria. Like Klebsiella, E. coli, and the other gram-negatives, Enterobacter species have developed broad-spectrum resistance to multiple classes of antibiotics. One drug, tigecycline, might work against these infections. There is nothing else in the pipeline.


Story Source:

The above story is based on materials provided by Infectious Diseases Society of America. Note: Materials may be edited for content and length.


Cite This Page:

Infectious Diseases Society of America. "No ESKAPE! New Drugs Against MRSA, Other Superbugs Still Lacking." ScienceDaily. ScienceDaily, 9 December 2008. <www.sciencedaily.com/releases/2008/12/081201105706.htm>.
Infectious Diseases Society of America. (2008, December 9). No ESKAPE! New Drugs Against MRSA, Other Superbugs Still Lacking. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2008/12/081201105706.htm
Infectious Diseases Society of America. "No ESKAPE! New Drugs Against MRSA, Other Superbugs Still Lacking." ScienceDaily. www.sciencedaily.com/releases/2008/12/081201105706.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins